Pharmacodynamics (PD)
Pharmacodynamics is the study of what a drug does to the body — the relationship between concentration at the target and the size, timing and direction of the biological effect.
Pharmacodynamics describes the concentration-to-effect half of drug action, the mirror of pharmacokinetics, which describes dose-to-concentration. Its standard model is the sigmoid Emax equation: effect rises with concentration toward a ceiling, with EC50 fixing the concentration that gives half that ceiling and the Hill coefficient fixing how steeply the curve climbs. Below the EC50 small concentration changes move the effect a lot; above it, large increases buy almost nothing.
In practice it is measured through markers chosen for the axis. For incretin agonists these include HbA1c, fasting and postprandial glucose, gastric emptying and body weight; the 68-week STEP 1 trial of semaglutide 2.4 mg reported mean weight change of about minus 15 percent against roughly minus 2.4 percent on placebo. For the growth hormone axis the workhorse is IGF-1, which integrates pulsatile secretion into a stable daily figure.
Pharmacodynamics determines whether a kinetic property matters. A long half-life helps only if effect tracks concentration; where the response is driven by receptor activation that persists after clearance, or by a downstream change taking days to reverse, effect duration and plasma duration come apart. Linking the two lets a dosing interval be chosen from data rather than convenience.
The recurring mistake is treating a pharmacodynamic marker as a clinical outcome. A compound that moves a biomarker has demonstrated pharmacology, not benefit, and biomarker reasoning has repeatedly failed at the outcome stage. The related error is importing a PD effect across species: a peptide that shifts a rodent marker at exposures far above anything achievable in a human tells you the receptor exists, and little more.